Effect of mouse nerve growth factor combined with mecobalamine on treatment of diabetic peripheral neuropathy

摘要

Objective:To observe the clinical effect of mouse nerve growth fact (NGF) combined with mecobalamine on treatment of diabetic peripheral n-europathy (DPN).Methods:A total of 84 cases of patients with DPN treated in ourhospital between April 2012 and June 2015 were selected, and divided into study group and control group randomly (n=42); Control group was only given mecobalamine treatment, while study group was given mouse nerve growth factor combined with mecobalamine treatment for 4 weeks. TThe motor nerve conduction velocity median nerve (MNCV), sensory nerve conduction velocity (SNCV), serum high sensitivity c-reactive protein (hs-CRP) and Toronto clinical scoring system (TCSS) changes of median nerve and nervus peroneus communis before and after treatment were compared. Results:There were no significant differences in MNCV, SNCV of mediannerve and nervus peroneus communis before treatment. MNCV and SNCV of both groups after treatment were significantly increased. MNCV, SNCV of mediannerve and nervus peroneus communis in study group was significantly higher than that in control group. hs-CRP and TCSS scoring of both groups before treatment showed no statistic significant difference. hs-CRP scoring of both groups after treatment showed no significant difference. TCSS scoring was significantly lower than that in control group. Adverse reaction total occurrence rate after given drug in study group was 16.67% (7/42), compared with 7.14% (3/42) in control group, difference was significant.Conclusions:Mouse NGF combined with mecobalamine could achieve good curative effect. It is of higher safety in the treatment of patients with DPN, and deserves popularization and application.